Molecular gate keepers succumb to gene aberrations in colorectal cancer in Kashmiri population, revealing a high incidence area

Saudi Journal of Gastroenterology

Volumn 15, Issue 4, 2009, Pages 244-252

  Sameer, A Syed ^a,b   Ul Rehman, Shakeel ^a   Pandith, Arshad A ^a   Syeed, Nidda ^a   Shah, Zaffar A ^a   Chowdhri, Nissar A ^a   Wani, Khursheed A ^a   Siddiqi, Mushtaq A ^a  

^a SHER I KASHMIR INSTITUTE OF MEDICAL SCIENCES   (India)

^b Clinical Biochemistry   (India)

Author keywords

Colorectal cancer; Dukes stage; K ras; Kashmir; P53; PCR SSCP

Indexed keywords

ADENINE NUCLEOTIDE; GUANINE NUCLEOTIDE; PROTEIN P53; PYRIMIDINE NUCLEOTIDE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER SURGERY; CODON; COLORECTAL CANCER; COLORECTAL SURGERY; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENE INSERTION; GENE MUTATION; HUMAN; HUMAN TISSUE; INDIA; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; MISSENSE MUTATION; MOLECULAR DYNAMICS; NONSENSE MUTATION; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; SINGLE STRAND CONFORMATION POLYMORPHISM;

COLORECTAL NEOPLASMS; FEMALE; GENES, P53; GENES, RAS; HUMANS; INCIDENCE; INDIA; MALE; MUTATION;

EID: 70349795803     PISSN: 13193767     EISSN: 19984049     Source Type: Journal    
DOI: 10.4103/1319-3767.56102     Document Type: Article

References (46)

1. Kemp Z, Thirlwell C, Sieber O, Silver A, Tomlinson I. An update on the genetics of colorectal cancer. Hum Mol Genet 2004;13:R177-85.
2. American Cancer Society: Cancer Facts and Figures 2008. Atlanta, Ga: American Cancer Society; 2008.
3. Akkiprik M, Ataizi-Çelikel C, Düünceli F, Sönmez O, Güllüoglu BM, Sav A, et al. Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers. J Gastrointest Liver Dis 2007;16:11-17
4. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-532
5. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767
6. Risques RA, Moreno V, Rias M, Marcuello E, Capella G, Peinado MA. Genetic pathways and genome wide determinants of clinical outcome in colorectal cancer. Cancer Res 2003;63:7206-7214
7. Takayama T, Miyanishi K, Hayashi T, Sato Y, Niitsu Y. Colorectal cancer: Genetics of development and metastasis. J Gastroenterol 2006;41:185-192
8. Harris AL. Mutant p53: The commonest genetic abnormality in human cancer. J Pathol 1990;162:5-6.
9. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Clearly K, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-708
10. Samowitz WS, Curtin K, Ma KN, Edwards S, Schaffer D, Leppert MF, et al. Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer 2002;99:597-602.
11. Tortola S, Marcuello E, Gonzalez I, Reyes G, Arribas R, Aiza G, et al. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. J Clin Oncol 1999;17:1375-1378
12. Hernandez-Boussard T, Rodriguez-Tome P, Montesano R, Hainaut P. IARC p53 mutation database: A relational database to compile and analyze p53 mutations in human tumors and cell lines: International Agency for Research on Cancer. Hum Mutat 1999;14:1-8.
13. Soong R, Powell B, Elsaleh H, Gnanasampanthan G, Smith DR, Goh HS, et al. Prognostic significance of TP53g ene mutation in 995 cases of colorectal carcinoma: Influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer 2000;36:2053-2060
14. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, et al. Prevalence of ras mutations in human colorectal cancers. Nature 1987;327:293-297
15. Baker SK, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinoma. Science 1989;244:217-221
16. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-456
17. Harris CC, Hollstein M. Clinical implication of the p53 tumor suppressor gene. N Engl J Med 1993;329:1318-1327
18. Remvikos Y, Laurent-Puig P, Salmon RJ, Frelat G, Dutrillaux B, Thomas G. Simultaneous monitoring of p53 protein and DNA content of colorectal adenocarcinomas by flow cytometry. Int J Cancer 1990;45:450-456
19. Borrensen-Dale A, Lothe RA, Meling GI, Hainut P, Rognum TO, Skovlund E. TP53 and long-term prognosis in colorectal cancer: Mutations in the L3 zinc-binding domain predict poor survival. Clin Cancer Res 1998;4:203-210
20. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001;1:233-240
21. Vidaurreta M, Maestro ML, Sanz-Casla MT, Rafael S, Veganzones S, de la Orden V, et al. Colorectal carcinoma prognosis can be predicted by alterations in gene p53 exons 5 and 8. Int J Colorectal Dis 2008;23:581-586
22. Watzinger F, Lion T. RAS family. Atlas Genet Cytogenet Oncol Haematol 1999. http://AtlasGeneticsOncology.org/Deep/Ras.html.
23. Khosrave-far R, Der CJ. The ras signal transduction pathway. Cancer Metastasis Rev 1994;13:67-89.
24. Fearon ER. Molecular genetic studies of the adenoma-carcinoma sequence. Adv Intern Med 1994;39:123-146
25. Bazan V, Migliavacca M, Zanna I, Tubiolo C, Grassi N, Latteri MA, et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 2002;13:1438-1446
26. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single strand conformation polymorphism. Proc Natl Acad Sci USA 1989;86:2766-2770
27. Bassam BJ, Caetano-Anolles G, Gresshoff PM. Fast and sensitive silver staining DNA in polyacrylamide gels. Anal Biochem 1991;196:80-83
28. Bosari S, Marchetti A, Battita F, Graziani D, Borsani G, Loda M, et al. Detection of p53 mutations by single strand conformation polymorphism (SSCP) gel electrophoresis: A comparative study of radioactive and non radioactive silver-stained SSCP analysis. Diagn Mol Pathol 1995;4:249-255
29. Sameer AS, Chowdhri NA, Abdullah S, Shah ZA, Siddiqi MA. Mutation pattern of K-ras gene in colorectal cancer patients of Kashmir: A report. Indian J Cancer 2009;3:219-225
30. Cho Y, Gorina S, Jeffrey PD, Pavletich N P. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 1994;265:346-355
31. Kressner U, Inganas M, Byding S, Blikstad I, Pahlman L, Glimelius B, et al. Prognostic value of p53 genetic change in colorectal cancer. J Clin Oncol 1999;17:593-599
32. Tortola S, Marcuello E, Gonzalez I, Reyes G, Arribas R, Aiza G, et al. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. J Clin Oncol 1999;17:1375-1381
33. Overgaard J, Yilmaz M, Guldberg P, Hansen LL, Overgaard J. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. Acta Oncol 2000;39:327-333
34. Dix BR, Robbins P, Soong R, Jenner D, House AK, Iacopetta BJ. The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer 1994;59:747-751
35. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, et al. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994;106:42-48
36. Goh H, Yao J, Smith DR. p53 point mutation and survival in colorectal cancer patients. Cancer Res, 1995;55:5217-5222
37. Bosari S, Viale G, Roncalli M, Graziani D, Borsani G, Lee AK, et al. p53 Gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol 1995;147:790-798
38. Borresen-Dale A, Lothe RA, Meling GI, Hainaut P, Rognum TO, Skovlund E. TP53 and long. term prognosis in colorectal cancer: Mutations in the L3 Zinc-binding domain predict poor survival. Clin Cancer Res 1998;4:203-210
39. Rabes HM. DNA adducts and cell cycle. J Cancer Res Clin Oncol 1986;58:4023-4037
40. Servomaa K, Kiuru A, Kosma VM, Hirvikoski P, Rytömaa T. p53 and K-ras gene mutations in carcinoma of the rectum among Finnish women. J Clin Pathol Mol Pathol 2000;53:24-30.
41. Kumar R, Mende P, Tricker AR, Siddiqi M, Preussmann R. N-nitroso compounds and their precursor in Brassica Oleracea. Cancer Lett 1990;54:61-65
42. Pfeifer G P, Denissenko M F, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking associated cancers. Oncogene 2002;21: 7435-7451
43. Miyaki M, Lijima T, Ishii R, Kita Y, Koike M, Kuroki T, et al. Increased frequency of p53 mutation in sporadic colorectal cancer from cigarette smokers. Jpn J Clin Oncol 2002;32:196-201.
44. Wójcik P, Kulig J, Okón K, Zazula M, Moździoch I, Niepsuj A, et al. KRAS mutation profile in colorectal carcinoma and novel mutation-internal tandem duplication in KRAS. Pol J Pathol 2008;59:93-96
45. Morin M, Kelly M, Barrett N, Delany P. Mutations of K-ras and p53 genes in colorectal cancer and their prognostic significance. Gut 1994;35:1627-1631
46. Al-Mulla F, Goingñ JJ, Sowden E T, Winter A, Pickford IR, Birnie GD. Heterogeneity of mutant versus wild-type in primary and metastatic colorectal carcinomas and association of codon12 valine with early mortality. J Pathol 1998;185:130-138